Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Estrogen Receptor Positive|HER2/Neu Negative|Invasive Breast Carcinoma|Multifocal Breast Carcinoma|Postmenopausal|Progesterone Receptor Positive|Stage I Breast Cancer|Stage IA Breast Cancer|Stage IB Breast Cancer|Stage II Breast Cancer|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage III Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer
Interventions: PROCEDURE: Biopsy of Breast|DRUG: Copanlisib|OTHER: Laboratory Biomarker Analysis|DRUG: Letrozole|DRUG: Palbociclib|OTHER: Pharmacological Study
Sponsor: Jonsson Comprehensive Cancer Center
Collaborators: Bayer|Translational Research in Oncology-U.S. Inc. (TRIO-US)